Lipocine (LPCN) Cash & Equivalents (2011 - 2025)

Lipocine (LPCN) has 15 years of Cash & Equivalents data on file, last reported at $14.2 million in Q4 2025.

• Quarterly Cash & Equivalents fell 34.28% year-over-year to $14.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.2 million (down 34.28% YoY) and the FY2025 annual result came in at $14.2 million, down 34.28% from the prior year.
• Cash & Equivalents declined to $14.2 million in Q4 2025, from $15.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $45.9 million in Q2 2021 to a low of $14.2 million in Q4 2025.
• A 5-year average of $27.2 million and a median of $24.2 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 231.35% — and 2025, when it tumbled 34.28%.
• Tracing LPCN's Cash & Equivalents over 5 years: stood at $45.8 million in 2021, then retreated by 29.93% to $32.1 million in 2022, then slumped by 31.54% to $22.0 million in 2023, then decreased by 1.72% to $21.6 million in 2024, then plunged by 34.28% to $14.2 million in 2025.
• The last three Cash & Equivalents figures came in at $14.2 million (Q4 2025), $15.1 million (Q3 2025), and $17.6 million (Q2 2025), per Business Quant data.